13-Nov-2025 5:30 AM CST - Business Wire Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate and pipeline updates. Both tibulizumab studies advanced during the quarter, said Kiran Nistala, MBBS, PhD, Chief Medical Officer and Head of Development at Z
20-Aug-2025 5:30 AM CST - Business Wire Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today announced that its senior leadership team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 4, 2025, at 2:45 PM ET in New York, NY. The Company will also conduct one-on-one investor me
14-Aug-2025 7:15 AM CST - Business Wire Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. The second quarter of 2025 marked continued progress across our clinical programs and organizational goals, said Robert Li
8-May-2025 5:30 AM CST - Business Wire Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. The first quarter of 2025 reflected steady progress across our clinical and operational priorities, said Robert Lisicki, Chief Executive Offi
25-Mar-2025 5:30 AM CST - Business Wire Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2024 financial results and recent corporate updates. In 2024, we reached key milestones that reinforced our financial foundation, expanded our leadership team, and advanced our clinical pipeline, highlighting our commitment to establishing a le
24-Feb-2025 5:30 AM CST - Business Wire Zura Bio to Present at the Leerink Partners Global Healthcare Conference $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 p.m. ET, and will host investor meetings in Miami, FL. A live webcast and a replay of the presentation
25-Nov-2024 5:30 AM CST - Business Wire Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 9:00 a.m. ET, and will host investor meetings in New York, NY. A live webcast and a replay of the presen
7-Nov-2024 5:30 AM CST - Business Wire Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 trial of tibulizumab in SSc. Weve worked closely with our contract research organization (CRO) to
30-Oct-2024 5:30 AM CST - Business Wire Zura Bio to Participate in Two Upcoming Investor Conferences in November $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in two investor conferences in November. Conference Details: Event:Guggenheim Inaugural Healthcare Innovation Conference Details:Participating in a fireside chat onTuesday, November 12, 2024, at 1:00 p.m. ET
13-Nov-2025 5:30 AM CST - Business Wire Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate and pipeline updates. Both tibulizumab studies advanced during the quarter, said Kiran Nistala, MBBS, PhD, Chief Medical Officer and Head of Development at Z
20-Aug-2025 5:30 AM CST - Business Wire Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today announced that its senior leadership team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 4, 2025, at 2:45 PM ET in New York, NY. The Company will also conduct one-on-one investor me
14-Aug-2025 7:15 AM CST - Business Wire Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. The second quarter of 2025 marked continued progress across our clinical programs and organizational goals, said Robert Li
8-May-2025 5:30 AM CST - Business Wire Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. The first quarter of 2025 reflected steady progress across our clinical and operational priorities, said Robert Lisicki, Chief Executive Offi
25-Mar-2025 5:30 AM CST - Business Wire Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2024 financial results and recent corporate updates. In 2024, we reached key milestones that reinforced our financial foundation, expanded our leadership team, and advanced our clinical pipeline, highlighting our commitment to establishing a le
24-Feb-2025 5:30 AM CST - Business Wire Zura Bio to Present at the Leerink Partners Global Healthcare Conference $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 p.m. ET, and will host investor meetings in Miami, FL. A live webcast and a replay of the presentation
25-Nov-2024 5:30 AM CST - Business Wire Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 9:00 a.m. ET, and will host investor meetings in New York, NY. A live webcast and a replay of the presen
7-Nov-2024 5:30 AM CST - Business Wire Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 trial of tibulizumab in SSc. Weve worked closely with our contract research organization (CRO) to
30-Oct-2024 5:30 AM CST - Business Wire Zura Bio to Participate in Two Upcoming Investor Conferences in November $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in two investor conferences in November. Conference Details: Event:Guggenheim Inaugural Healthcare Innovation Conference Details:Participating in a fireside chat onTuesday, November 12, 2024, at 1:00 p.m. ET
